Johnson Fistel is investigating Elevance Health, Inc. following the company's disclosure that the Centers for Medicare & Medicaid Services intends to impose intermediate sanctions, including suspension of enrollment into certain Medicare Advantage-Prescription Drug plans effective March 31, 2026. The law firm is examining whether Elevance and its executives complied with federal securities laws. Investors who suffered losses are encouraged to contact the firm.
Elevance Health, Inc. (ELV)
Common Stock · Currency in USD · XNYS
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Company Info
SIC6324
Composite FIGIBBG000BCG930
CIK0001156039
IPOOct 30, 2001
Sectorhospital & medical service plans
Highlights
Market Cap$66.06B
EPS$21.28
P/E Ratio13.91
Revenue$200.97B
Gross Profit$181.32B
Net Income$4.75B
Employees97,100
WSO219,664,888
Phone(800) 331-1476
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Elevance Health, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Elevance Health, Inc. (ELV) has returned -14.26% so far this year and -28.64% over the past 12 months. Looking at the last ten years, ELV has achieved an annualized return of -4.69%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
ELV
1M4.16%
6M-15.02%
YTD-14.26%
1Y-28.64%
5Y-9.15%
10Y-4.69%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Elevance Health, Inc. (ELV) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.43% | -6.51% | -7.08% | 2.70% | ||||||||
| 2025 | 6.27% | 0.21% | 8.74% | -3.96% | -8.25% | 1.74% | -27.25% | 11.42% | 1.14% | -2.11% | 6.40% | 4.08% |
| 2024 | 4.60% | 2.13% | 3.79% | 2.35% | 2.61% | 1.48% | -1.73% | 4.34% | -6.50% | -22.37% | -0.50% | -9.76% |
| 2023 | -1.71% | -5.88% | -0.97% | 0.25% | -4.48% | -1.22% | 6.57% | -6.47% | -2.33% | 3.23% | 6.90% | -1.43% |
| 2022 | -0.70% | -0.67% | 2.13% | -6.89% | 20.14% | -2.22% | -4.20% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Elevance Health, Inc. (ELV) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ELV compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Elevance Health, Inc. volatility is 1.54%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Liabilities And Equity (USD) | 121.49B | 116.89B | 108.93B | 102.77B |
| Equity Attributable To Parent (USD) | 43.88B | 41.32B | 39.31B | 36.31B |
| Equity Attributable To Noncontrolling Interest (USD) | 144.00M | 111.00M | 99.00M | 87.00M |
| Equity (USD) | 44.03B | 41.43B | 39.41B | 36.39B |
| Other Non-current Liabilities (USD) | 4.54B | 4.02B | 2.84B | 2.83B |
| Long-term Debt (USD) | 31.90B | 30.87B | 24.90B | 23.85B |
| Noncurrent Liabilities (USD) | 36.43B | 34.88B | 27.73B | 26.68B |
| Current Liabilities (USD) | 41.04B | 40.58B | 41.79B | 39.70B |
| Liabilities (USD) | 77.47B | 75.46B | 69.52B | 66.38B |
| Other Non-current Assets (USD) | 42.61B | 41.20B | 34.27B | 32.52B |
| Intangible Assets (USD) | 11.20B | 12.09B | 10.27B | 10.32B |
| Fixed Assets (USD) | 4.68B | 4.65B | 4.36B | 4.32B |
| Noncurrent Assets (USD) | 58.49B | 57.95B | 48.90B | 47.16B |
| Current Assets (USD) | 63.00B | 58.94B | 60.03B | 55.62B |
| Assets (USD) | 121.49B | 116.89B | 108.93B | 102.77B |
News and Insights
Elevance Health (ELV) stock declined 7.23% on Monday after the Centers for Medicare & Medicaid Services (CMS) froze the company's Medicare Advantage enrollment effective March 31, 2026. The freeze stems from alleged noncompliance with risk adjustment data submission requirements, including the company's repeated use of USB drives instead of CMS-mandated electronic systems since November 2018. This regulatory action compounds earlier concerns from the company's weak 2026 guidance and CMS's proposed minimal payment increases for Medicare Advantage plans.
Humana shares plummeted 13.49% in premarket trading following the Trump administration's proposal for nearly flat Medicare Advantage payment rates for 2027, with only a 0.09% net average payment increase versus Wall Street expectations of 4-6%. The broader health insurance sector also suffered significant losses, with CVS Health, UnitedHealth Group, and Elevance Health all declining sharply.
The Centers for Medicare & Medicaid Services (CMS) proposed a 2027 Medicare Advantage payment increase of only 0.09%, significantly below Wall Street's expectations of 4-6%. This modest growth announcement triggered sharp declines in major health insurer stocks, with UnitedHealth, Humana, and CVS Health leading the losses. The CMS emphasized program sustainability and payment accuracy through updated risk adjustment models.
UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.
The US stock market is positioned for a strong start to 2026 with the S&P 500 near record highs above 6,900 points. Three beaten-down stocks showing recovery potential are highlighted: Flowco Holdings, which is forming a rounding pattern with upside toward $26; Elevance Health, testing resistance at $360 with potential to reach $450; and Matador Resources, supported by strong fundamentals and a 50% fair value gap.
Hyperion Capital Advisors acquired 540,000 shares of Vertex (VERX) worth $13.39 million in Q3, making it the fund's third-largest holding. Despite a 63% stock decline over the past year, the investment signals confidence in Vertex's underlying business fundamentals, including 12.7% revenue growth, 30% cloud revenue growth, and strong cash generation with a $150 million share buyback authorization.
The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.
With market volatility increasing, the article highlights three dividend-paying stocks that reported strong Q3 earnings: Travelers Companies, Elevance Health, and Church & Dwight. These stocks offer potential stability and consistent income amid uncertain market conditions.
Molina Healthcare reported disappointing annual guidance, causing stocks of healthcare insurance providers Centene and Oscar Health to decline. The company expects higher medical cost trends across segments, particularly in the Marketplace, impacting investor confidence.